TaiRx, Inc. focuses on the development and commercialization of therapeutics for the treatment of cancer and other diseases. The company’s products under development include CVM-1118, an oral anti-cancer drug that is Phase II clinical trial. Its pre-clinical products comprise TRX-920, an oral delivery formulation; and TRX-105, a molecule developed for treating and alleviating symptoms of various colitis. The company also offers Zelnite, a drug that helps in treatment of selenium deficiency; and focuses on development of the nodal diagnostic devices and anti-body drugs. The company was founded in 2011 and is based in Taipei, Taiwan.
Metrics to compare | 6580 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship6580PeersSector | |
|---|---|---|---|---|
P/E Ratio | −16.3x | −35.3x | −0.5x | |
PEG Ratio | −0.58 | −0.27 | 0.00 | |
Price/Book | 4.0x | 4.9x | 2.6x | |
Price / LTM Sales | 150.0x | 72.0x | 3.3x | |
Upside (Analyst Target) | - | 0.0% | 46.2% | |
Fair Value Upside | Unlock | −23.9% | 6.6% | Unlock |